Wuhan Easy Diagnosis Biomedicine Co (002932) Fair Value & Analysis
Healthcare · CN · Market cap 3.5B CNY
Fair value as of: Jul 22, 2026
From 3 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥22.83 to ¥24.70 (+8.2%) since Jun 25, 2026. Share price +3.1% over the past month.
Below-average quality, screening 67% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain.
- The model range is unusually wide (¥11.09 to ¥42.67). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥13.88 – ¥46.74 · fair‑value band ¥11.09 – ¥42.67 · the ¥14.77 price screens below the ¥24.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Wuhan Easy Diagnosis Biomedicine Co (002932) currently trades at ¥14.77, while our model-based Fair Value estimate is ¥24.70, implying the stock looks roughly 67.2% undervalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Wuhan Easy Diagnosis Biomedicine Co generated revenue of 266M CNY at a net margin of -5.0%. Revenue grew 1.0% year over year. It earns a return on equity of -1.2%. The balance sheet holds a net cash position of 485M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥11.09 (bear case) to ¥42.67 (bull case); at ¥14.77, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 67%, 002932 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Dividend Discount (¥17.12) versus Asset-Based (¥15.93). Highest evidence: Gordon GGM (70).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services.
Full company description
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware products. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Wuhan Easy Diagnosis Biomedicine Co reported revenue of ¥265M in FY2025 versus ¥2.8B in FY2021, a compound −44.7%/yr. Reported net income was −¥16.5M in FY2025.
Watch 002932: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Wuhan Easy Diagnosis Biomedicine Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wuhan Easy Diagnosis Biomedicine Co (002932) overvalued or undervalued?
What is the fair value of 002932?
What is the quality score of 002932?
What is the revenue of Wuhan Easy Diagnosis Biomedicine Co (002932)?
What is the net profit margin of 002932?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Wuhan Easy Diagnosis Biomedicine Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.